Yüklüyor......
Prolonged low intensity EPOCH–rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy
Burkitt lymphoma is an aggressive form of non-Hodgkin lymphoma that has a short doubling time, thus intense short-cycle chemotherapy has been thought to be essential. A recent NCI-sponsored clinical trial investigated DA-EPOCH-R given to 19 HIV-negative patients and a short course regimen (SC-EPOCH-...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Landes Bioscience
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4128854/ https://ncbi.nlm.nih.gov/pubmed/24919059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.29504 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|